From PsychonautWiki
Jump to navigation Jump to search

This article is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

Fluoxetine is an antidepressant substance of the selective serotonin reuptake inhibitor (SSRI) class. It is a widely prescribed psychiatric medication used in the treatment of depression, obsessive compulsive disorder, and bulimia nervosa.[citation needed]

It is worth noting that antidepressants like fluoxetine have limited recreational potential. They may also reduce the action of certain serotonergic substances such as psychedelics and entactogens.

Individuals who are prescribed SSRIs that seek to use hallucinogenic substances for psychonautic or recreational purposes are advised to research potential interactions beforehand. It is usually advised to taper off any SSRIs before engaging in hallucinogen use.


Fluoxetine acts by inhibiting the presynaptic reuptake of the neurotransmitter serotonin, resulting in higher levels of 5-hydroxytryptamine (5-HT) in various areas of the brain.

It is 5-HT selective due to its high affinity for 5-HT transporters, weak affinity for noradrenaline transporters and lack of affinity for dopamine transporters.[1]

Among approved antidepressants, fluoxetine may be less effective than newer agents such as escitalopram.[2] However, its very long elimination half-life of 1–3 days (acute) and 4–6 days (chronic)[3] makes it attractive as a treatment for SSRI withdrawal symptoms.[4]

Subjective effects

This subjective effects section is a stub.

As such, it is still in progress and may contain incomplete or wrong information.

You can help by expanding or correcting it.

Toxicity and harm potential


This toxicity and harm potential section is a stub.

As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it.
Note: Always conduct independent research and use harm reduction practices if using this substance.


  1. Fluoxetine, DrugBank 
  2. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. (April 2018). "Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis". Lancet. 391 (10128): 1357–1366. doi:10.1016/S0140-6736(17)32802-7. PMC 5889788Freely accessible. PMID 29477251. 
  3. Altamura AC, Moro AR, Percudani M (March 1994). "Clinical pharmacokinetics of fluoxetine". Clinical Pharmacokinetics. 26 (3): 201–14. doi:10.2165/00003088-199426030-00004. PMID 8194283.  Unknown parameter |s2cid= ignored (help)
  4. . doi:10.1017/S1461145708008493Freely accessible.  Missing or empty |title= (help)